Compares embolic materials for blocking a blood vessel in chronic subdural hematoma
Tests particles, liquid embolics and coils in adults with chronic subdural hematoma.
Plain-language title generated from the registry record
Registry title: Comparative Study of Embolic Agents in Patients With Subdural Hemorrhage Undergoing Middle Meningeal Artery (MMA) Embolization
Key facts
- Where
- Sioux Falls, United StatesSee the site
Where in United States
- Sanford USD Medical CenterSioux Falls, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sanford Health
- Trial code
- NCT07757113
- Record updated
- 11 August 2026
- Original description
Single site, prospective, comparative effectiveness pilot trial comparing efficacy and safety outcomes of three embolic materials (particles, liquid embolics, and Wallaby Phenox coils) in MMA embolication for cSDH.Read full original descriptionShow less
Comparative Study of Embolic Agents in Patients With Subdural Hemorrhage Undergoing Middle Meningeal Artery (MMA) Embolization
Single site, prospective, comparative effectiveness pilot trial comparing efficacy and safety outcomes of three embolic materials (particles, liquid embolics, and Wallaby Phenox coils) in MMA embolication for cSDH.
Inclusion: Adult patients (≥ 18 years); Undergoing Middle Meningeal Artery Embolization (MMAE) for chronic subdural hematoma (cSDH); Able to provide informed consent or have a legally authorized representative (LAR) do so.
Exclusion: Known severe allergy or contraindication to embolic materials (e.g. particles, liquids like Onyx/n-BCA, or coils); Inability to undergo angiography (e.g. severe renal impairment contraindicating contrast); Ineligible for MMAE procedure, as deemed by the treating physician, for any indication (e.g. pregnancy); Non-chronic subdural hematoma (cSDH) indications for Middle Meningeal Artery Embolization (MMAE), including acute subdural hematoma with symptom onset < 72 hours or mixed acute/chronic without predominant chronic features; Pregnancy or breastfeeding; Inability or unwillingness to complete follow-up visits at 30 and 90 days.